<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234919</url>
  </required_header>
  <id_info>
    <org_study_id>19-2946</org_study_id>
    <nct_id>NCT04234919</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Cell Free DNA in Lung Transplant</brief_title>
  <acronym>LoSt</acronym>
  <official_title>A Longitudinal Study of Donor-Derived Cell Free DNA in Lung Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplant is a viable treatment strategy for many with end-stage lung diseases. Despite
      advances in both the surgical and medical management, lung transplant recipients experience
      episodes of allograft insult and injury that lead to dysfunction and ultimately contribute to
      graft failure. The primary noninvasive tool for monitoring the lung allograft, pulmonary
      function testing, is neither sensitive nor specific for lung allograft injury which makes the
      management of lung transplant recipients particularly challenging. A decline in pulmonary
      function tests prompts invasive procedures such as bronchoscopy with transbronchial lung
      biopsy to diagnose the cause of allograft injury, although this, too, is not 100% sensitive,
      and oftentimes patients are treated empirically for rejection when no other etiology for lung
      function decline is identified. Empiric treatment prompted by extrapulmonary drivers of
      decline in lung function may result in inappropriate exposure to risks of augmented
      immunosuppression. The purpose of this study is to determine to what extent monitoring of
      donor-derived cell free DNA in lung transplant recipients can be used as a marker of lung
      injury and stability.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 9, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship</measure>
    <time_frame>12 Months</time_frame>
    <description>Determine the relationship between donor derived cell free DNA and lung allograft function during the first year after lung transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Assessments</measure>
    <time_frame>12 Months</time_frame>
    <description>Quantitative assessments of dd-cfDNA obtained at pre-specified timepoints post-transplant compared to clinical events (PGD scores, detection of allograft dysfunction, rejection, or infection).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Consented adult lung transplant recipients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with end stage lung disease who are placed on the lung transplant waitlist
        for consideration of a bilateral transplant at the University of Colorado lung transplant
        program will be recruited for participation in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  Actively listed or have recently had a double lung transplant

          -  Participant is willing and able to provide informed consent

        Exclusion Criteria:

          -  Prior organ transplantation

          -  Transplantation performed in the setting of hospitalization for acute illness or
             decompensation

          -  Unable or unwilling to consent for enrolment

          -  Single lung transplant recipient

          -  Consideration for multi-organ transplantation

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice L Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodan Stumph, MPH</last_name>
    <phone>303-724-6052</phone>
    <email>jordan.stumph@cuanschutz.edu</email>
  </overall_contact>
  <reference>
    <citation>Chambers DC, Cherikh WS, Goldfarb SB, Hayes D Jr, Kucheryavaya AY, Toll AE, Khush KK, Levvey BJ, Meiser B, Rossano JW, Stehlik J; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018 Oct;37(10):1169-1183. doi: 10.1016/j.healun.2018.07.020. Epub 2018 Aug 11.</citation>
    <PMID>30293613</PMID>
  </reference>
  <reference>
    <citation>Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008 May 1;177(9):1033-40. doi: 10.1164/rccm.200706-951OC. Epub 2008 Feb 8.</citation>
    <PMID>18263803</PMID>
  </reference>
  <reference>
    <citation>Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, Glanville AR. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med. 2004 Nov 1;170(9):1022-6. Epub 2004 Aug 5.</citation>
    <PMID>15297270</PMID>
  </reference>
  <reference>
    <citation>Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant. 2005 Aug;5(8):2022-30.</citation>
    <PMID>15996255</PMID>
  </reference>
  <reference>
    <citation>Morrell MR, Pilewski JM, Gries CJ, Pipeling MR, Crespo MM, Ensor CR, Yousem SA, D'Cunha J, Shigemura N, Bermudez CA, McDyer JF, Zeevi A. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant. 2014 Dec;33(12):1288-94. doi: 10.1016/j.healun.2014.07.018. Epub 2014 Aug 23.</citation>
    <PMID>25443870</PMID>
  </reference>
  <reference>
    <citation>Kulkarni HS, Bemiss BC, Hachem RR. Antibody-mediated Rejection in Lung Transplantation. Curr Transplant Rep. 2015 Dec;2(4):316-323. Epub 2015 Sep 30.</citation>
    <PMID>27896040</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, Ensor CR, Gottlieb J, Hachem RR, Lama V, Martinu T, Neil DAH, Singer LG, Snell G, Vos R. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019 May;38(5):493-503. doi: 10.1016/j.healun.2019.03.009. Epub 2019 Apr 3.</citation>
    <PMID>30962148</PMID>
  </reference>
  <reference>
    <citation>Glanville AR, Verleden GM, Todd JL, Benden C, Calabrese F, Gottlieb J, Hachem RR, Levine D, Meloni F, Palmer SM, Roman A, Sato M, Singer LG, Tokman S, Verleden SE, von der Thüsen J, Vos R, Snell G. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019 May;38(5):483-492. doi: 10.1016/j.healun.2019.03.008. Epub 2019 Apr 3.</citation>
    <PMID>31027539</PMID>
  </reference>
  <reference>
    <citation>Glanville AR. Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med. 2010 Apr;31(2):208-21. doi: 10.1055/s-0030-1249117. Epub 2010 Mar 30. Review.</citation>
    <PMID>20354933</PMID>
  </reference>
  <reference>
    <citation>Rademacher J, Suhling H, Greer M, Haverich A, Welte T, Warnecke G, Gottlieb J. Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures. Transplant Res. 2014 May 27;3:11. doi: 10.1186/2047-1440-3-11. eCollection 2014.</citation>
    <PMID>24917927</PMID>
  </reference>
  <reference>
    <citation>Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, Hachem R, Hayes D Jr, Neil D, Reinsmoen NL, Snyder LD, Sweet S, Tyan D, Verleden G, Westall G, Yusen RD, Zamora M, Zeevi A. Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016 Apr;35(4):397-406. doi: 10.1016/j.healun.2016.01.1223. Epub 2016 Feb 10. Review.</citation>
    <PMID>27044531</PMID>
  </reference>
  <reference>
    <citation>Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2014 Dec;33(12):1273-81. doi: 10.1016/j.healun.2014.07.012. Epub 2014 Jul 21.</citation>
    <PMID>25130554</PMID>
  </reference>
  <reference>
    <citation>Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest. 2013 Jul;144(1):226-233. doi: 10.1378/chest.12-0587.</citation>
    <PMID>23328795</PMID>
  </reference>
  <reference>
    <citation>Bharat A, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg. 2010 Oct;90(4):1094-101. doi: 10.1016/j.athoracsur.2010.06.009.</citation>
    <PMID>20868794</PMID>
  </reference>
  <reference>
    <citation>Akbarpour M, Wu Q, Liu X, Sun H, Lecuona E, Tomic R, Bhorade S, Mohanakumar T, Bharat A. Clinical relevance of lung-restricted antibodies in lung transplantation. Hum Immunol. 2019 Aug;80(8):595-601. doi: 10.1016/j.humimm.2019.04.016. Epub 2019 May 8. Review.</citation>
    <PMID>31078336</PMID>
  </reference>
  <reference>
    <citation>Emtiazjoo AM, Wilkes DS. Humoral immunity and the development of obliterative bronchiolitis after lung transplantation: is there a link? Am J Respir Cell Mol Biol. 2013 Feb;48(2):145-9. doi: 10.1165/rcmb.2012-0349RT. Epub 2012 Oct 18. Review.</citation>
    <PMID>23087052</PMID>
  </reference>
  <reference>
    <citation>Weigt SS, Wang X, Palchevskiy V, Gregson AL, Patel N, DerHovanessian A, Shino MY, Sayah DM, Birjandi S, Lynch JP 3rd, Saggar R, Ardehali A, Ross DJ, Palmer SM, Elashoff D, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction. PLoS One. 2017 Jan 19;12(1):e0169894. doi: 10.1371/journal.pone.0169894. eCollection 2017.</citation>
    <PMID>28103284</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

